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Summary The purpose of this study was to review the efficacy of a protracted venous infusion of 5-fluorouracil (PVI 5-FU)-based
chemotherapy in advanced small bowel adenocarcinoma. Data on all patients with small bowel malignancy who were seen at a single
institution over a 5-year period were retrieved from the gastrointestinal unit and hospital databases, and these cases were reviewed. Eight
patients with advanced small bowel adenocarcinoma received PVI 5FU-based chemotherapy. The overall response rate in assessable
patients was 37.5% (3/8). The median overall survival was 13 months (range 1-28), and progression-free survival was 7.8 months (range
0-15). Overall, the treatment was well tolerated and symptomatic benefit was seen. In conclusion, PVI 5-FU has activity in this disease. This
should be assessed either as a single agent or as part of a combination regimen such as epirubicin/cisplatin/PVI FU (ECF) in a multicentre
randomized study.
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Although adenocarcinoma is the most common small bowel
tumour, it still represents less than 1% ofgastrointestinal (GI) tract
tumours. The standard treatment is surgery with a resection rate of
35-77%. The operative mortality of surgery with a curative intent
is 0-18% and the 5-year survival is 10-62% (Delcore et al, 1993;
Ouriel and Adams, 1984). The role of radiotherapy and chemo-
therapy is less clear. There are reports of prolonged survival with
combination chemo- and radiotherapy following palliative bypass
surgery or incomplete resection and reports suggesting a better
prognosis compared with pancreatic carcinoma (Sakker and Ware,
1973; Yeung et al, 1993). Data on the use of chemotherapy alone
are limited. Regimens used have been very varied, and some series
have been collected over prolonged periods (Sakker and Ware,
1973; Okhusa et al, 1991).
METHODS
The GI unit and hospital databases were searched for patients
referred to the Royal Marsden Hospital (RMH) with malignancy
of the small bowel during the period 1990-95. Pathology was
reviewed at RMH before treatment. Data regarding diagnosis,
treatment, toxicity and response were collected prospectively.
Responses were assessed according to the WHO criteria (Miller et
al, 1981). Symptomatic responses were recorded prospectively on
the GI database; improvement was defined as disappearance of a
symptom for >3 weeks. Toxicity was assessed according to the
National Cancer Institute's common toxicity criteria (National
Cancer Institute, 1988).
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Chemotherapy
Protracted venous infusion of5-fluorouracil (PVI 5FU) was admin-
istered via a portable infusion pump and Hickman line as previ-
ously described (Hill et al, 1995). In the epirubicin/cisplatin/PVI
5FU regimen (ECF), 5FU was commenced at a dose of200 mg m-2
day-'. Epirubicin (50 mg m-2) and cisplatin (60 mg m-2) were given
every 3 weeks with short-course hydration and antiemetic prophyl-
axis. PVI 5FU was commenced at a dose of 300 mg m-2 day-'
as a single agent or in combination with mitomycin C (MMC)
(10 mg m-2 q6 weekly). Management of toxicities were as
described previously (Bamias et al, 1996).
RESULTS
Between 1990 and 1995, eight patients received palliative
chemotherapy for advanced small bowel adenocarcinoma. Patient
characteristics are detailed in Table 1. Histology review confirmed
adenocarcinoma of local origin in seven patients. In one patient
(patient 8), no biopsy material was available. This patient had a
macroscopically malignant tumour arising in the second part of
duodenum extending into the head of the pancreas. Multiple open
and endoscopic biopsies failed to confirm adenocarcinoma; the
patient eventually progressed with liver metastases eight months
after finishing ECF. The remaining patients had either incom-
pletely resected locally invasive primaries, or had lymph node or
distant metastases. One patient had a prior history of prostatic
carcinoma pre-dating small bowel adenocarcinoma; death was
attributable to the small bowel disease. One patient had a prior
history ofCrohn's disease.
Toxicity
Treatment was generally well tolerated, with toxicity mainly
limited to grade 0-2. Grade 3 toxicity occurred in two patients
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Table 1 Patient characteristics
Patient Age Sex Site Metastases Chemo Best PFS OS
(years) response (months)
1 53 M Ileum LN + liver 5FU + MMC SD 10 months 17
2 33 M Jejunum LN + omentum ECF CR 11 months 18
3 54 F Ileum LN + liver PVI 5FU PR 15 months 28
(ECF/MMC on (2nd PR
relapse) after
relapse)
4 42 M Duodenum Liver ECF PR 6 months 8
5 52 F Jejunum abdominal wall ECF SD 6 months 9
6 36 M Duodenum LN PVI 5FU PD 3 months 6
7 39 M Duodenum Locally invasive ECF PD 2 weeks 1
progressed
within 2 weeks
obstruction
8 55 F Duodenum Locally invasive ECF SD 13 months 18
PFS, progression free survival; OS, overall survival. LN, lymph nodes. Radiological response: CR, complete response; PR, partial response; SD; stable
disease; PD, progressive disease; NE, not evaluable.
with palmar-plantar erythema (PPE). One further patient had
grade I PPE. All cases ofPPE occurred after 6 weeks' exposure to
5FU, and the grade 3 reactions responded to a dose reduction of
5FU. Diarrhoea, grade 1-2, occurred in four patients and grade 2
nausea or vomiting in four. Grade 2 alopecia occurred in three of
the seven patients who received ECF. No other patients experi-
enced more than grade 1 alopecia. Nadir blood counts were not
routinely measured, but no patient developed neutropenia-related
infections or bleeding complications. Two patients experienced
central venous line complications, one had line-related shoulder
pain and one a venous thrombosis requiring line removal.
Response and survival
All eight patients were assessable for response. Responses for
initial chemotherapy included one complete response (CR) and
two partial responses (PR), giving a combined response rate of
37% (3/8). The median progression free survival was 7.8 months
(range 0-15) and median overall survival was 13 months (range
1-28). All patients treated had advanced disease and have subse-
quently died.
The patient who had a radiological CR had omental and lymph
node metastases at presentation, all these tissues returned to within
radiologically normal limits. This response was not confirmed
histologically and the patient relapsed after eleven months. Two
patients progressed while undergoing chemotherapy, including
one early progression (< 2 weeks) and three patients remained
stable. Four patients who were symptomatic, with weight loss,
anorexia or abdominal pain, all improved. WHO performance
status (PS) improved in two patients (PS 2 -> 1), one of whom
subsequently had a PR, and one progressed later while still on
treatment. PS deteriorated in two patients, one of whom
progressed with bowel obstruction within days of treatment (PS 2
-* 4), the second (PS 0 -* 1) had stable disease. In the remaining
patients, PS was stable. Although intermittent mild nausea was
common (7/8 > grade 1), appetite only decreased in three and
weight was stable or increased in all except two patients.
DISCUSSION
This series represents a consecutive group ofpatients referred to a
single institution, treated over a five-year period with PVI 5FU-
based chemotherapy and analysed on an intention-to-treat basis.
The most frequently used combination in our series was ECF. All
patients received PVI 5FU-based therapy, mitomycin-C was the
only other drug used. The response rate of37% suggests that small
bowel adenocarcinoma, like other adenocarcinomas of the GI
tract, is sensitive to PVI 5FU-based regimens. The four sympto-
matic patients all improved. Only one patient experienced a treat-
ment-related deterioration in PS, other patients maintained a PS of
2. Although the series is small, the results in terms of overall
survival, symptomatic responses, the improvement or maintenance
ofa good PS as an indicator ofquality oflife and the generally low
toxicity of therapy, suggests that there may be benefit of 5FU-
based chemotherapy compared with palliative surgery alone
(Sakker and Ware, 1973; Rotman et al, 1994). Various series or
case reports have suggested that small bowel adenocarcinoma is a
chemo- or radiosensitive disease, particularly in comparison with
pancreatic cancer (Sakker and Ware, 1973; Jigyasu et al, 1984;
Okhusa et al, 1991; Yeung et al, 1993; Coia et al, 1994). A series
of fourteen patients, collected over a 30-year period and treated
predominantly with 5-fluorouracil (5FU) containing regimens,
reported one partial response (PR) lasting 12 weeks and 11
patients with minor responses or stable disease. The overall
median survival for all patients was 9 months from start of treat-
ment (Jigyasu et al, 1984).
The most frequently used regimen in this series was ECF. This
has been used widely in gastrointestinal adenocarcinomas since it
was first reported in 1990 (Cunningham et al, 1990). In one study,
274 patients with oesophagogastric adenocarcinoma were
randomized between ECF and FAMTX (5FU, doxorubicin and
methotrexate). This demonstrated the superiority of ECF with an
overall response rate of 45%. vs 21% (P = 0.002), and a small but
significant survival advantage (Webb et al, 1997). Similarly, PVI
5FU has been used either alone or in combination in oesophageal,
gastric, pancreatic as well as colonic adenocarcinomas with
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response rates of 20-70% (Hill et al, 1995; Bamias et al, 1996;
Webb et al, 1997). Our data suggest that adenocarcinoma of the
small bowel may be similarly sensitive to PVI 5FU and this should
be the basis for further study.
SUMMARY
This series demonstrates that small bowel adenocarcinoma
responds to PVI 5FU chemotherapy and treatment is well toler-
ated. The efficacy of ECF in upper GI adenocarcinoma makes it a
rational choice. The rarity ofthese tumours means that single insti-
tution trials of PVI 5FU are unlikely to be feasible, but could be
addressed as a pan-European randomized trial.
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